PMID- 33470480
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20220323
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 38
IP  - 6
DP  - 2021 Jun
TI  - Impact of clinical pharmacy interventions on health and economic outcomes in type 
      2 diabetes: A systematic review and meta-analysis.
PG  - e14526
LID - 10.1111/dme.14526 [doi]
AB  - AIM: To examine the effectiveness of clinical pharmacy interventions on health 
      and economic outcomes of people with type 2 diabetes in hospital settings. 
      METHODS: We searched MEDLINE, EMBASE, PsycInfo, CINAHL, COCHRANE Library and 
      citations and reference lists of key articles. We included randomized and 
      non-randomized controlled trials, cohort and controlled before-after studies. 
      Primary outcomes were glycosylated haemoglobin (HbA(1c) ), all-cause mortality, 
      major cardiovascular events, adverse events (AEs), health-related quality of life 
      and economic outcomes. RESULTS: We retrieved 11,853 studies, of which 44 studies 
      were included in the review (n = 8623). We included 29 randomized controlled 
      studies in the meta-analyses (n = 4055). Clinical pharmacy interventions 
      significantly reduced HbA(1c) levels compared to usual care (standardized mean 
      difference: -0.52, p < 0.001). The interventions significantly reduced AEs 
      compared to usual care. No studies were reported on the effectiveness of clinical 
      pharmacy interventions on major cardiovascular events. In one study that examined 
      the impact of clinical pharmacy interventions on all-cause mortality, a 
      non-significant reduction was observed compared with usual care. There was 
      significant improvement in quality of life and significant reduction in costs of 
      type 2 diabetes care compared to usual care. CONCLUSIONS: Clinical pharmacy 
      interventions were effective in improving glycaemic control, quality of life and 
      reducing the rate of AEs and costs of type 2 diabetes care.
CI  - (c) 2021 Diabetes UK.
FAU - Desse, Tigestu A
AU  - Desse TA
AUID- ORCID: 0000-0002-6116-0433
AD  - School of Nursing and Midwifery, Centre for Quality and Patient Safety Research, 
      Institute for Health Transformation, Faculty of Health, Deakin University, 
      Burwood, Vic., Australia.
FAU - Vakil, Krishna
AU  - Vakil K
AD  - School of Medicine, Faculty of Health, Deakin University, Burwood, Vic., 
      Australia.
FAU - Mc Namara, Kevin
AU  - Mc Namara K
AD  - School of Medicine, Faculty of Health, Deakin University, Burwood, Vic., 
      Australia.
FAU - Manias, Elizabeth
AU  - Manias E
AD  - School of Nursing and Midwifery, Centre for Quality and Patient Safety Research, 
      Institute for Health Transformation, Faculty of Health, Deakin University, 
      Burwood, Vic., Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20210314
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Controlled Before-After Studies/*methods
MH  - Diabetes Mellitus, Type 2/*drug therapy/economics/epidemiology
MH  - Global Health
MH  - *Health Care Costs
MH  - Humans
MH  - Hypoglycemic Agents/economics/*therapeutic use
MH  - Morbidity/trends
MH  - *Quality of Life
OTO - NOTNLM
OT  - clinical pharmacy interventions
OT  - diabetes
OT  - health outcomes
OT  - type 2 diabetes
EDAT- 2021/01/21 06:00
MHDA- 2022/03/24 06:00
CRDT- 2021/01/20 08:43
PHST- 2020/12/17 00:00 [revised]
PHST- 2020/09/23 00:00 [received]
PHST- 2021/01/18 00:00 [accepted]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
PHST- 2021/01/20 08:43 [entrez]
AID - 10.1111/dme.14526 [doi]
PST - ppublish
SO  - Diabet Med. 2021 Jun;38(6):e14526. doi: 10.1111/dme.14526. Epub 2021 Mar 14.